CSC Pharmaceuticals International




Proleukin Injection


Proleukin Injection

nterleukin
-
2 (aldesleukin, [Proleukin
®])
is a cytokine with the following immune
-
modulating effects: enhancement of lymphocyte mitogenesis and cytotoxicity, induction of
lymphocyte
-
activated (LAK) cells and natural killer (NK) cells, and induction of interferon
gamma production. U.S. Food and D
rug Administration (FDA)
-
approved labeled
indications include the treatment of metastatic renal cell carcinoma and metastatic
malignant melanoma. Other oncologic applications of IL
-
2 monotherapy are being actively
investigated, principally as a technique
to maintain remission or eliminate minimal residual
disease in patients with a variety of malignancies, including most prominently leukemias,
but also including lymphomas and other solid tumors such as neuroblastoma and breast
cancer. IL
-
2 has also been u
sed post
-
autologous bone marrow transplantation as an
immunotherapeutic technique to maintain remission and reduce the relapse rate.
In HIV
-
infected patients, there is a reduced endogenous production of IL
-
2 and a defect in
IL
-
2 receptor expression, respon
sible in part for the characteristic reduction in CD4 counts.
Exogenous IL
-
2, in conjunction with antiretroviral therapy, has been investigated as a
technique to increase CD4 counts, preserve immune function and hopefully decrease the
incidence of opportu
nistic infections. It has been proposed that IL
-
2 in conjunction with
combination antiretroviral therapy may be a useful approach for purging HIV from the
latently infected CD4 cells.
IL
-
2 has also been investigated as a component of a variety of combinat
ion therapies, for
example in combination with interferon alpha in the treatment of metastatic renal cell
cancer and metastatic melanoma. IL
-
2 can be administered by subcutaneous injection
(low
-
dose therapy) or into a vein (intermediate or high
-
dose thera
py), either intermittently
as a bolus or quick injection, or as a continuous treatment over a defined period of time




Enquiry Form

* fields are mandatory Enquiry Details
* Subject :
* Details :
Contact Information
* Your Name :
* Your Company Name :   Not Applicable
* Select Country :
* E-mail :  
* Mobile No. :